Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis.

Erol V, Avci E, Kabukcu Hacioglu S, Guler N, Akgun Cagliyan G, Ünver Koluman B, Kendir IC, Elver O, Kara K, Kaya E, Alayvaz Aslan N

Cureus30 Nov 2025

PMID41479490PMCIDPMC12754562DOI10.7759/cureus.98204PepBankPUB-41479490

Download PDF PubMedAsk about this study

Jump to 3 results

Summary

ObjectivesThis study evaluated whether serum levels of mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) could provide prognostic insights in patients newly diagnosed with multiple myeloma (MM), particularly in relation to therapeutic responsiveness.MethodsIn a prospective analysis involving 29 MM patients, serum MOTS-c concentrations were measured before and after frontline treatment. Associations between MOTS-c fluctuations and clinical-biochemical variables were systematically explored.ResultsPatients who responded to treatment exhibited a substantial post-therapy increase in MOTS-c levels, while refractory cases showed little to no change. Post-treatment MOTS-c values inversely correlated with calcium and neutrophil count changes. Despite limited standalone predictive capacity, MOTS-c dynamics may reflect microenvironmental and metabolic adaptation linked to treatment response.ConclusionsChanges in serum MOTS-c concentrations following therapy may serve as complementary markers of clinical response in MM. Further validation in larger cohorts is warranted.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with multiple myeloma, post-treatment serum MOTS‑c values correlated inversely with changes in calcium and neutrophil count.
In plain wordsIn people with myeloma, higher body's own MOTS‑c levels after treatment were linked to smaller rises in calcium and neutrophils.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of post-treatment MOTS-c with calcium and neutrophil count changes
Study
n = 29
Outcome group
Mitochondrial function · Cancer
Source sentences
Summary
Post-treatment MOTS-c values inversely correlated with calcium and neutrophil count changes.
1 context sentence(design, population, supporting numbers)
Summary · context
In a prospective analysis involving 29 MM patients, serum MOTS-c concentrations were measured before and after frontline treatment.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-4147949003
02HumanEndogenous levelObservational studyOther
In patients with newly diagnosed multiple myeloma, serum MOTS‑c levels increased substantially after therapy in treatment responders.
In plain wordsIn people with newly diagnosed myeloma, the body's own MOTS‑c levels rose after treatment in those who responded.
Peptide
MOTS-c
Outcome
IncreaseChange in serum MOTS-c after treatment in responders
Study
n: not reported in source
Outcome group
Mitochondrial function · Cancer
Source sentences
Summary
Patients who responded to treatment exhibited a substantial post-therapy increase in MOTS-c levels
1 context sentence(design, population, supporting numbers)
Summary · context
In a prospective analysis involving 29 MM patients, serum MOTS-c concentrations were measured before and after frontline treatment.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-4147949001
03HumanEndogenous levelObservational studyOther
In patients with newly diagnosed multiple myeloma, serum MOTS‑c levels showed little to no change after therapy in refractory cases.
In plain wordsIn people with newly diagnosed myeloma, the body's own MOTS‑c levels barely changed after treatment in those who did not respond.
Peptide
MOTS-c
Outcome
No significant changeChange in serum MOTS-c after treatment in refractory cases
Study
n: not reported in source
Outcome group
Mitochondrial function · Cancer
Source sentences
Summary
refractory cases showed little to no change.
1 context sentence(design, population, supporting numbers)
Summary · context
In a prospective analysis involving 29 MM patients, serum MOTS-c concentrations were measured before and after frontline treatment.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-4147949002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.